Current Report Filing (8-k)
May 16 2022 - 4:25PM
Edgar (US Regulatory)
0001522767
false
0001522767
2022-05-10
2022-05-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 10, 2022
MARIMED INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
0-54433 |
|
27-4672745 |
(State or other jurisdiction |
|
(Commission |
|
(IRS Employer |
of incorporation) |
|
File Number) |
|
Identification No.) |
10
Oceana Way, Norwood, Massachusetts |
|
02062 |
(Address of principal executive
offices) |
|
(Zip Code) |
Registrant’s
telephone number, including area code: (617) 795-5140
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act: None.
Title
of each class |
|
Ticker
symbol(s) |
|
Name
of each exchange on which registered |
Not Applicable. |
|
Not Applicable. |
|
Not Applicable. |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02. Results of Operations and Financial Condition.
On
May 10, 2022, MariMed Inc. (the “Company”) issued a press release, a copy of which is attached hereto as Exhibit 99.1
and is incorporated herein by reference, announcing its financial results for the three-month period ended March 31, 2022.
Item 7.01. Regulation FD Disclosure.
On
May 11, 2022, the Company hosted a conference call for investors to discuss its financial condition and operating results for the three
month period ended March 31, 2022, as well as other relevant matters. The Company used an Investor Presentation on the call, which is
posted on the Company’s website at https://ir.marimedinc.com/. A transcript of the call and a copy of the Investor Presentation
are attached hereto as Exhibit 99.2 and 99.3, respectively.
The
information furnished pursuant to this Item 7.01 shall not be deemed to constitute an admission that such information is required to
be furnished pursuant to Regulation FD or that such information or exhibits contain material information that is not otherwise publicly
available. In addition, the Company does not assume any obligation to update such information in the future.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits
In
accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, furnished pursuant to Items
2.02 and 7.01, including Exhibits 99.1 and 99.2, respectively, shall not be deemed to be “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that
section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act
of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
**********
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
MARIMED INC. |
|
|
|
Dated:
May 16, 2022 |
|
|
|
By: |
/s/
Susan M. Villare |
|
|
Susan M. Villare, Chief
Financial Officer |
MariMed (QX) (USOTC:MRMD)
Historical Stock Chart
From Jul 2024 to Aug 2024
MariMed (QX) (USOTC:MRMD)
Historical Stock Chart
From Aug 2023 to Aug 2024